SCHEMBL6429116

SCHEMBL6429116

Cn1cc(NC(=O)OC(C)(C)C)cc1C(=O)Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.38
CYP17A1 P05093 3/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
HDAC3 O15379 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
PRKDC P78527 1/20 0.37
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
DRD2 P14416 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
ACHE P22303 1/20 0.35
BACE1 P56817 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
PSMB8 P28062 1/20 0.35
NAMPT P43490 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1845748 0.87 MAPK14 (0.39) MAPK14CYP17A1CA12CA1CA9
SCHEMBL2392134 0.85 HDAC3 (0.39) MAPK14CYP17A1CA12CA1CA9
SCHEMBL14878099 0.85 CCNC (0.39) MAPK14CYP17A1CA12CA1CA9
SCHEMBL6429813 0.84 MAPK14 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL14355717 0.82 TOP1 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL5001090 0.82 TOP1 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL15385155 0.82 TOP1 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL5000911 0.82 TOP1 (0.40) MAPK14CYP17A1CA12CA1CA9
SCHEMBL3939869 0.81 P2RY12 (0.42) HDAC3HDAC8HDAC1HDAC2HDAC6
SCHEMBL3929339 0.81 P2RY12 (0.42) HDAC3HDAC8HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924396-B2 α-haloenamine reagents PHARMACIA CORPORATION (US) 2005-08-02 US disclosed
CN-1561326-A Alpha-haloenamine reagents PHARMACIA CORP (US) 2005-01-05 CN disclosed
EP-1430028-A2 AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES Pharmacia Corporation (US) 2004-06-23 EP disclosed
EP-1421056-A1 (ALPHA)-HALOENAMINE REAGENTS Pharmacia Corporation (US) 2004-05-26 EP disclosed
US-20040092770-A1 Alpha-haloenamine reagents PHARMACIA CORPORATION 2004-05-13 US disclosed
US-6677487-B2 COMBINING A TERTIARY AMIDE WITH A PENTAVALENT PHOSPHOROUS HALIDE IN A SOLVENT TO FORM AN ALPHA - HALOIMINIUM SALT AND CONVERTING THE ALPHA -HALOIMINIUM SALT TO THE ALPHA -HALOENAMINE WITH A BASE PHARMACIA CORPORATION 2004-01-13 US disclosed
US-20030105279-A1 Aromatic and heteroaromatic acid halides for synthesizing polyamides PHARMACIA CORPORATION 2003-06-05 US disclosed
US-20030080320-A1 Alpha- haloenamine reagents PHARMACIA CORPORATION 2003-05-01 US disclosed
WO-2003020684-A1 (ALPHA)-HALOENAMINE REAGENTS PHARMACIA CORPORATION (US) 2003-03-13 WO disclosed
WO-2003018552-A2 AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES PHARMACIA CORPORATION (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030080320-A1 Alpha- haloenamine reagents HNMT, HDHD5, NISCH MAPK14 4763/4885CYP17A1 3289/4885CA12 634/4885
US-20040092770-A1 Alpha-haloenamine reagents HNMT, HDHD5, NISCH MAPK14 4763/4885CYP17A1 3289/4885CA12 634/4885
US-20030105279-A1 Aromatic and heteroaromatic acid halides for synthesizing polyamides AAAS, HTT, HRH4 MAPK14 2774/4885CYP17A1 4439/4885CA12 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.